
Bioorganic and Medicinal Chemistry Letters p. 853 - 856 (1999)
Update date:2022-08-05
Topics:
Vince, Robert
Brownell, Jay
Akella, Lakshmi B.
The inhibition of glyoxalase I enzyme to increase cellular levels of methylglyoxal has been developed as a rationale for the production of anticancer agents. Synthesis of a peptidomimetic analog of the previously prepared potent glyoxalase inhibitor, S-(p-bromobenzyl)glutathione (PBBG), was accomplished by inserting a urea linkage, NH-CO-NH, to replace the γ- glutamyl peptide bond. Thus, the target compound, γ-(L-γ-azaglutamyl)-S- (p-bromobenzyl)-L-cysteinylglycine 6, was a potent inhibitor of glyoxalase I with almost no loss of activity when compared to PBBG. However, unlike PBBG, 6 was completely resistant to enzymatic degradation by kidney homogenate or by purified γ-glutamyltranspeptidase enzyme.
View MoreContact:+86-571-86491666
Address:SHI XIANG ROAD
SHAANXI TOP PHARM CHEMICAL CO.LTD
Contact:+86-029-85733403
Address:No.108 ,west sector,south er huan,xi'an,china
Contact:86 311 85902108 / 85902109
Address:room 1001-1005 ,huanghe Road ,shijiazhuang ,China
Qingdao Kingway Pharmtech Co., Ltd.
Contact:86-532-87118899
Address:No. 88, Middle Haixi Road, Jiaonan City, Qingdao, China
Xian Changyue Biological Technology Co., Ltd.
website:https://www.xachangyue.com/
Contact:+86-029-88211911
Address:Keji Road NO.70
Doi:10.1016/j.tet.2013.10.024
(2013)Doi:10.1055/s-2001-18706
(2001)Doi:10.1016/S0022-328X(00)86348-2
(1968)Doi:10.1021/ic50075a007
(1969)Doi:10.1016/S0040-4039(01)88000-X
(1969)Doi:10.1021/om990023q
(1999)